Inte:Ligand

Inte:Ligand

Vienna, Austria· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.8M

Overview

Inte:Ligand is a long-established, private Austrian company specializing in computer-aided drug design (CADD) software and services. Its flagship product, LigandScout, is a well-cited platform for structure- and ligand-based pharmacophore modeling, virtual screening, and molecular docking, aimed at improving early-stage discovery efficiency. The company operates a hybrid business model, generating revenue through software licensing and expert consulting services for clients worldwide, positioning itself as a technology enabler rather than a drug developer.

AI / Machine LearningSmall Molecules

Technology Platform

LigandScout software suite for pharmacophore-based virtual screening and molecular docking, integrated with AI/ML technologies. Includes ilib diverse for virtual library generation.

Funding History

2
Total raised:$5.8M
Series A$5M
Grant$800K

Opportunities

Growing demand for computational efficiency in drug discovery to reduce R&D costs and timelines.
Expansion of AI/ML applications in life sciences and potential entry into new markets like cosmetics and agrochemicals.
Opportunity to transition software to cloud-based SaaS models.

Risk Factors

Intense competition from larger informatics companies and well-funded AI-driven drug discovery startups.
Risk of technological obsolescence if platform does not rapidly integrate advanced AI methods.
Reliance on a limited client base in the cyclical pharmaceutical R&D sector.

Competitive Landscape

Operates in a crowded field with competitors ranging from large software vendors (e.g., Dassault Systèmes BIOVIA, Schrödinger) to specialized CADD/AI startups (e.g., Atomwise, BenevolentAI). Differentiation is based on deep expertise in pharmacophore modeling, user-friendly interface, and a hybrid software-plus-services model.